No headlines found.
Nu.Q Vet Cancer Test launched in-clinic in U.S. and Europe through Antech
PRNewswire (Tue, 23-Apr 8:00 AM ET)
VolitionRx Limited Announces Full Fiscal Year 2023 Financial Results and Business Update
PRNewswire (Mon, 25-Mar 4:10 PM ET)
PRNewswire (Thu, 21-Mar 8:30 AM ET)
Volition and Fujifilm Vet Systems Launch Nu.Q Vet Cancer Test in Japan
PRNewswire (Wed, 20-Mar 8:30 AM ET)
Volition appoints Dr Andrew Retter as Chief Medical Officer
PRNewswire (Tue, 19-Mar 4:30 PM ET)
Volition to Share Nu.Q NETs Strategy Update at Upcoming Webinar
PRNewswire (Fri, 2-Feb 8:00 AM ET)
VolitionRX Ltd is a United States-based epigenetics company that applies its Nucleosomics platform through its subsidiaries to develop simple, easy-to-use, cost-effective blood tests to help diagnose and monitor a range of life-altering diseases including some cancers and diseases associated with NETosis such as sepsis and COVID-19. The tests are based on the science of Nucleosomics, which is the practice of identifying and measuring nucleosomes in the bloodstream or other bodily fluid - an indication that disease is present. The company is focused on human diagnostics and monitoring but also has a subsidiary focused on animal diagnostics and monitoring.
Volitionrx trades on the AMEX stock market under the symbol VNRX.
As of April 24, 2024, VNRX stock price declined to $0.80 with 146,604 million shares trading.
VNRX has a beta of 0.77, meaning it tends to be less sensitive to market movements. VNRX has a correlation of 0.01 to the broad based SPY ETF.
VNRX has a market cap of $65.65 million. This is considered a Micro Cap stock.
Last quarter Volitionrx reported $243,973 in Revenue and -$.11 earnings per share. This fell short of revenue expectation by $-206,027 and met earnings estimates .
In the last 3 years, VNRX stock traded as high as $4.14 and as low as $.55.
The top ETF exchange traded funds that VNRX belongs to (by Net Assets): VXF, IWC.
VNRX has underperformed the market in the last year with a return of -54.8%, while the SPY ETF gained +24.2%. In the last 3 month period, VNRX fell short of the market, returning -24.5%, while SPY returned +4.6%. However, in the most recent 2 weeks VNRX has outperformed the stock market by returning +9.4%, while SPY returned -2.7%.
VNRX support price is $.80 and resistance is $.91 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that VNRX stock will trade within this expected range on the day.